Hansa Biopharma lures Pfizer exec to head up US business

Swedish rare disease specialist Hansa Biopharma (STO: HNSA) today announced today that Matthew Shaulis will join the company effective March 16 as chief commercial officer and president of its US affiliate. He will report to president and chief executive Søren Tulstrup and join the Executive Committee.

With over 20 years of US and international experience in the pharmaceutical industry, Mr Shaulis joins Hansa Biopharma from US pharma giant Pfizer (NYSE: PFE), where he has held several senior executive roles, including president, inflammation and immunology for the International Developed Markets, president, North America Oncology, and, most recently, senior vice president responsible for the company’s global commercial and medical go-to-market model transformation. Prior to Pfizer, Matthew held roles of increasing responsibility in global strategic marketing and sales leadership, strategic customer group management and licensing and acquisition as well as in product and indication launches across multiple disease areas at Teva, Cephalon, Johnson & Johnson, and Schering-Plough.

Underscores goal of bringing imlifidase to the USA